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Abstract 
Background: Recently, much attention has been directed towards considering activated microgelial cells  as 
putative  targets for treatment of neurological disorders. MigriHeal®  as a novel herbal remedy was introduced   for  
the treatment of  migraine headaches.  The previous researches has shown that MigriHeal® extracts can decrease NO 
in  an in vitro inflammatory model. The aim of this study was to investigate the effect of MigriHeal® on NO 
generation from LPS- stimulated microglia cells. Materials and Methods: Neonatal rat primary microglial cells 
were isolated from the mixed glial cultures and the purity of the cultures was determined by immunocytochemistry. 
Microglial cells were pretreated with Migri-Heal® and activated by 1μg/ml LPS. Subsequently, NO levels in the 
culture supernatants were measured by a griess reaction. Our results showed that Migri-Heal® 50μg/ml significantly 
reduced NO level in inflamed microglia in a dose-dependent manner.  Results: The results showed that different  
concentrations of Migri-Heal® had no prominent effect on cell viability in presence of LPS as compared with the 
control group.  In addition, the pretreatment of microglia cells with Migri-Heal®  can prevent from a morphological 
changes of the cells into the round and phagocytic shape. Conclusion: Our study demonstrated that MigriHeal® 
might have NO scavenging properties. Integrative studies are warranted to uncover the   novel pharmacological 
insights of this herbal remedy as an putative   therapeutic approach  against diseases - associated with inflammation.  
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Microglial cells - the smallest glial cells that 
constitute approximately 15% of the population of 
brain cells - are primary immune cells that regulate 
the innate immunity and participate in adaptive 
immune responses in the neural tissue (1).  These cells 
also are considered as specific macrophages which 
could phagocytose  and protect neurons in the central 
nervous system (CNS).  
Microglial cells , as a result of  exposure to 
inflammatory stimuli and  several pathological 
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conditions (such as injury and ischemia) can rapidly 
activate ,thereby  amplifying, immigrating to injured 
site, phagocytizing  cell cell debris  and producing 
neurotoxic and neurotropic agents(2). 
. Furthermore, it has been shown that 
proinflammatory and cytotoxic factors produced by 
microglial cells can induce neurodegeneration. 
 When neurons die, microglial cells become 
more active and change to phagocyte. The 
subsequent biological changes in active microglial 
cells can provide a complicated network of 
interaction between immune responses in CNS (3). 
For example, microglial cells through the 
secretion of cytokines and prostaglandins   can be 
considered as a signal for enhancement of 
inflammatory pathways is astrocytes. Furthermore, 
microglia activation could lead to release of  
inflammatory mediators ,thereby recruiting more 
number of microglial cells to the CNS (4). 
Moreover, it has been demonstrated that 
chronic activation of microglia has been associated 
with various neurodegenerative diseases (5, 6). 
For these reasons, much attention has been 
directed towards considering these cells as putative 
targets for treatment of neurological disorders. 
Recently, based on anecdotal evidence found 
in traditional Iranian medicine MigriHeal® as a 
novel herbal remedy was introduced in order to treat 
migraine headaches. This drug has been patented by 
the Invention and Patent Registration Office of I.R. 
of Iran .Notably, thus far, there e is no report on 
adverse effects of MigriHeal® in investigation 
performed on animal models and human.  
The previous researches in our laboratory have 
shown that MigriHeal® extracts can decrease NO in 
some inflammatory models (7, 8). Moreover, studies 
performed by our group demonstrated that some 
constituents of MigriHeal® decreased NO levels in 
endothelioma cell culture (9). 
Against the background of these findings, 
investigating the effect of MigriHeal® on NO 
generation from microglia cells stimulated with LPS 
for the first time may be useful to illustrate other 
therapeutic aspects of this herbal remedy in the 
neuroinflammatory diseases.  
Methods 
Reagents 
Fetal bovine serum (FBS), Dulbecco's Modified 
Eagle Medium (DMEM) and Griess reagent were 
purchased from Gibco BRL (Grand Island, NY, USA). 
Bacterial LPS (E5:055), and MTT kit (M2128 
500MG), Antibiotics including streptomycin and 
penicillin were purchased from Sigma Chemical Co. 
(St. Louis, MO, USA). FITC conjugated anti-OX42 
antibody to rat CD11b/c was from CALTAG (Sketty, 
Swansea). Dimethyl sulfoxide (DMSO) 
(1.02952.1000) was purchased from Merck and Migri-
Heal® was prepared by Dr Mohammad Ansari. 
Cell Culture 
Primary microglial cells were isolated from 
fetal brain of a 1-3 day old, Wistar rat, as previously 
described (10). Briefly, the cells were cultured in 
DMEM, supplemented with 100 UI/ml penicillin G, 
100 μg/ml streptomycin, and 20% FBS..Cells were   
seeded  on   polystyrene culture dishes (Nunc), and 
incubated in a humidified atmosphere with 5% CO2 at 
37°C. In order to  obtain primary microglia-rich mixed 
cultures, all media and the isolated tissues were re-fed 
with fresh medium supplemented with 10% FBS. 
Isolation of Microglia 
After reaching confluence at 12-14 days , the 
culture flasks were gently shaken in order to isolate 
microglial cells (figure2). Then,  the isolated microglia 
were divided into 24-wells plates (70.000 cells per 
well) and incubated under the previous conditions for 
24 hours. In order to measure the purity of the cells, 
the Immunocytochemistry (ICC) was carried out by 
using the OX-42 antibody against the CD11b protein. 
Immunocytochemistry (ICC)  
In order to measure the purity of the cells, the 
Immunocytochemistry (ICC) was carried out by using 
the OX-42 antibody against the CD11b protein. 
Briefly, the cells fixed with PBS containing 4% 
paraformaldehyde, became permeable with PBS 
containing 0.2% Triton x-100, and a blocker solution 
of PBS containing 3% BSA was added. Finally, the 
antibody which is conjugated with FITC (diluted with 
blocking solution) to be added to the cells. After one 
hour in room temperature, the cells were seen with 
fluorescence microscope with green filter (figure 4). 
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Migri-Heal® Extracts 
One hundred grams of Migri-Heal® powder 
were dissolved in 250 ml water, boiled for 10 
minutes, and subsequently filtered using a filter 
paper. Finally, Extract solutions was dried using 
Freeze Dryer system.  
One mg/ml of the dried Migri-Heal® extract 
was dissolved in DMEM and filtered by 0.22µm 
filter. This procedure was applied to prepare fresh 
Migri-Heal® extract for each time experiment. 
Extraction of the Essential Oil 
The essential oil was obtained from one 
hundred grams of Migri-Heal® powder using hydro 
distillation (4 hours) in a Clevenger-type apparatus. 
The essential oil yield was about 0.90% (v/w). The 
oil was dried with anhydrous sodium sulphate and 
stored at -20°C until use. 
Gas chromatography mass spectrometer (GC-
MS) 
Essential oil from Migri-Heal® was analyzed 
by a Thermoquest Trace gas chromatography (GC) 
(USA) connected to a Thermolinnigan Trace mass 
spectrometer (MS), Ionization mode EI, mass range 
37-457 m/z and interface and ion source 
temperatures 265 and 200°C, respectively. The 
device equipped with a 30 m × 0.25 mm × 0.25 µm 
DB-5MS (Agilent J&W Scientific). The oven 
temperature was programmed from 50°C, held 2 min, 
raised to 265°C at 2.5°C/min, and held for 20 min. 
The injector and detector temperatures were 265°C 
and 280°C, respectively. The carrier gas was helium 
at 1.5 ml/min and the split ratio was 1:100. The flow 
rate of the carrier gas (He) was 1.5 mL per min and 
the split ratio was 1:10. For the injection, 1 μl of 
essential oil diluted solution (1/100, v/v, in ethyl 
acetate) was injected manually in the split mode. 
Identification of the compounds was performed by 
comparison of their mass spectra with those of the 
Wiley libraries. 
Cell Treatment with Migri-Heal® 
The cells were treated with different doses of 
Migri-Heal® (25, 75, 100, 150 and 200 µg/ml) in 
fresh medium containing 1% fetal bovine serum 
(FBS) for  one hour, and then stimulated with 1μg/ml 




NO  production from cultured glia was 
measured using the Griess nitrite assay (1, 11). 
Briefly, the 50 µl of cell-free supernatant from each 
sample and equal amount of freshly prepared Griess 
reagent were added in duplicate to 96-well flat-bottom 
microtiter plates. Then the samples were incubated for 
15 min at room temperature. 
 The amount of nitrite was assessed by 
measuring its absorbance at 540 nm using a microplate 
reader (Labsystems Multiskan MS). 
Cell Viability Assay 
For the cell viability assay, MTT (3-4-5-
dimethylthiazole-2-yl-2, 5-diphenyl-tetrazolium 
bromide) solution (1 mg/ml) was added in a volume 
equal to 10% of DMEM and incubated for 4 hours at 
37°C in dark. Next, the solution was discarded and the 
formazan crystals formed within the cells were 
dissolved using DMSO (dimethylsulphoxide). The 
absorbance was measured at 540 nm using a 
microplate reader and the percentage survival of the 
cells, relative to untreated control cells, calculated. 
The experiments were run in triplicate and were 
repeated twice. It should be noted that, all condition 
was similar to the main experiments in current study. 
Statistical Analysis 
Statistical analysis of the study was performed 
by SPSS 16 software. One way ANOVA followed by 
the LSD test was used to determine the statistical 
differences among various cell groups. Values of 
P<0.05 were considered as significant. 
Results 
Growth of Primary Glial Cells   
Proceeding growth of microscopic glial cells 
during 2 weeks was considered, the results of this 
work are as follows (figure 1). The primary mixed 
glial cells were cultured after 12-14 days. 
Isolated microglial cell culture 
After the cells reached an appropriate 
confluency (at 12-14 days), the flasks were gently 
shaken in order to remove the microglial cells. 
Microglia cells were plated onto 24 well tissue 
culture plates (80000 cells/well) with the aim of 
confirming purity of microglia in the plates. The 
microglial cells   were isolated by gentle shaking 
(figure 2). The adherent microglia cells were cultured 
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for 24 h, and the purity of the cultures was more than 
95%, as judged with immunostaining with ICC 
method by using the OX-42 antibody against CD11b 
protein (figure 3). 
Microscopic investigations of microglial cells 
exposed to LPS and Migri-Heal® 
Using phase contrast microscope, we 
investigated the effects of LPS and Migri-Heal® on 
the cell morphology changes. 
Accordingly, it was observed that microglia 
cells activated with LPS had ameboid morphology 
(Figure.4b) as compared with ramified shape in 
untreated cells (Figure.4a) as control group. Also, the 
morphology of the cells pretreated with Migri Heal® 
(Figure.4c) had high similarity with control group. 
According to the figure 4c, effective concentration of 
Migri-Heal® on microglia cells is 50μg/ml (figure 4c). 
Effect of MigriHeal® on lipopolysaccharide-
induced NO production 
As represented in figure 5, the cells pretreated 
with MigriHeal® following stimulation with LPS after 
1h has decreased level of culture media nitrite in 
comparison with cells treated with LPS in dose -
dependent manner.  
 Our results demonstrated that in primary rat 
microglia activated by LPS, 50μg/ml of Migri-Heal® 
has a strong inhibitory effect on NO production from 
cells (P<0.05) (Figure 5). 
Analyses of Migri-Heal® by GC/MC 
The results of the analysis with GC/MC on The 
essential oils obtained from the Migri-Heal® Shows 
that, this mixture,  rich of  monoterpenoids such as 
thymol and α 1,8-Cineole, that occupying a dominant 
part of the Migri-Heal®. Our results Indicates that the 
majority of the Migri-Heal® is 21/16%, α 1, 8-Cineole 
and 13/1%, thymol. 
Evaluation of toxicity of Migri-Heal® 
concentrations 
We performed MTT assay in order to 
investigate that possibility of the cytotoxic action of 
Migri-Heal® on decrease in production of NO.The 
results showed that different concentration of  
Migri-Heal® had no prominent effect on cell 
viability in presence of LPS as compared with the 
control group (Figure 6). 
Discussion 
Inflammation is a phenomenon which has an 
important   role in the immune system. Within the 
brain, inflammatory pathways are initiated by 
microglia cells, which function as the resident 
macrophages of the central nervous system (CNS) 
(12). Under normal conditions, microglia cells, are 
effective in the maintenance and performance of the 
neurons. These cells rapidly activate and similar to 
 
Fig. 1. Growth of glial cells uring 2 weeks (A) 1st 
day, (B) 3rd Day, (C) 5th day, (D) 7th Day, (E) 
10th day, (F) 14th day  
 
 
Fig. 2. Isolation of microglial cells. (A), (B) 
Microglial cells in a mixed glial and neuron 




Fig. 3. Isolated microglia cells, 
immunostained with OX42 antibody against 
CD11b showed purity greater than 95%. 
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macrophage functions could phagocytose, secret pro-
inflammatory cytokines and present antigens to 
immune system thus can be considered as functional 
cells in response to pathological conditions (3, 12, 
13). 
Activated microglia cells with production of 
various proinflammatory cytokines and free radicals 
such as NO, play a pivotal role in the process of 
neuroinflammatory diseases. The dysregulation of  
inflammatory responses has a central role in   
pathogenesis of  multiple sclerosis, Parkinson’s 
disease, migraine, Alzheimer’s disease and even 
cerebral ischemia and traumatic brain injuries (for a 
review, see Ref. (14)]. The  high production of NO 
from the activated microglia has been demonstrated 
in several lines of evidence (15, 16). Also, it has been 
shown that excessive amount of NO could lead to 
neurodegenerative disorders (5). 
In accordance with the involvement of  NO  in  
migraine pathophysiology , Migri-Heal® reduces NO 
in patients who have decreased levels of melatonin  
(17-19). Interestingly, consistent with our finding that  
Migri-Heal® reduced  NO levels in LPS-induced 
primary microglial cells, other studies performed by 
our group demonstrated that some  constituents of 
MigriHeal® decreased NO levels in endothelioma cell 
culture (7, 8). 
Since increasing evidence is highlighting the 
emerging role of dysregulation of   function of 
endothelium system and microglia cell in pathogenesis 
of neurological disorders, particularly migraine, 
neuroinflammatory diseases,  stroke and 
neurodegenerative diseases, it can be deduced that 
Migri-Heal® through the regulation of these cells 
might be considered as a potential therapeutic 
approach, although  further in vivo and in vitro studies 
 
Fig. 4. Morphological changes of primary microglial cells. (A) Untreated microglial cells (negative 
control) which was ramified in comparison with LPS-treated microglial cells (B) LPS-treated microglial 
cells (positive control) which had amoeboid activated morphology (C) pretreated by 50 μg/ml Migri 
Heal®.(A,C Phase contrast [200×])(B Phase contrast [320×]). 
 
 
Fig. 5. Effect of Migri-Heal® in NO production in activated microglial cells. Microglia cells were 
pretreated with different doses of Migri-Heal®, after 1 h microglial cells were stimulated with LPS. After 
48 hours, nitrite concentration (µM) in culture media was assessed by Griess reaction. Amount of 50μg/ml 
Migri-Heal® has been shown maximum effects of anti-inflammatory. * Means p <0.05 compared with the 
groups treated with LPS 1μg/ml   
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are needed in this regard. 
Additionally, our result regarding the effect of 
the effects of MigriHeal® on basal and 
lipopolysaccharide (LPS)-induced NO levels are also 
consistent with recent study from our group ,which 
showed that hot water extract and essential oil of 
MigriHeal® can be suppressed the LPS induced NO 
in a dose-dependent manner in  Raw 264.7 cells (9). 
However, in contrast to Rafiee Kh et al. (9), 
the highest inhibition of NO generation by 
MigriHeal® treated samples vs. LPS alone occurred 
in 50μg/mL concentration during 48 h.  
The  analysis of Migri-Heal® by GC/MS 
showed that ®, 1,8-cineole and thymol are constitute, 
two major and principal compounds in Migri-Heal® 
.It has been illustrated that 1,8-cineole can inhibit 
antigen confliction - induced airway inflammatory 
symptoms in guinea pigs (20). It also suppressed 
arachidonic acid metabolism and reduced secretion 
of TNF-α, IL-1β, LTB 4 and TXB from  human 
blood monocytes (21, 22).Furthermore, Juergens et 
al. reported this element could decrease cytokine  
production from  LPS-stimulated monocytes and 
lymphocytes (23). 
Recently,it has been demonstrated that thymol  
suppressed expression of inducible nitric oxide 
synthase (iNOS)  in a dose –dependent manner in 
mouse mammary epithelial cells (24). 
Antioxidant and anti-inflammatory  properties 
of thymol  have been reported in human neutrophils 
and cell-free systems (25). 
In view of the low level of nocturnal melatonin 
in migraine patients during night in comparison to 
those in those in healthy subjects (18),on the other 
hand ,and the putative  function of melatonin as a 
scavenger of free radicals such as NO from biological 
environment (26), on one hand ,it is plausible that the 
effectiveness of MigriHeal® therapy may be 
associated with  high concentration of melatonin in 
some medicinal plants used for preparation of 
MigriHeal® (27). 
Also, it should be noted that the usefulness of 
MigriHeal® can be related to the combined action of 
secondary plant compounds. 
Although, the findings from the current study, 
together with previous investigations, may open novel 
therapeutic avenue for diseases that associated with 
disturbed nitric oxide homeostasis ,more investigations 
are required to clarify exact mechanism.  
Also, the results of this study as well as 
previous reports showed that LPS stimulation of 
microglia leads to a morphological change of the cells 
into the round and phagocytic shape, and increase the 
production of NO (28, 29). The current study pointed 
up the pretreatment of microglia cells with Migri-
Heal®  can prevent from a morphological change of 
the cells into the round and phagocytic shape. 
Collectively, our study demonstrated that 
MigriHeal® may has NO scavenging properties. 
Integrative studies are warranted to uncover the   novel 
 
Fig. 6. Effect of Migri-Heal® on cell viability viability after 48 hours. different concentration of Migri-
Heal® had no prominent effect on cell viability in presence of LPS as compared with the control group. 
Means P<0.05 compared with the group treated with LPS 1μg/ml. 
M: melatonin, L:LPS 
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pharmacological insights of this herbal remedy as a 
putative   therapeutic approach against diseases - 
associated with inflammation. 
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